Matching articles for "Jemperli"
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)
The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient…
Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e138 doi:10.58347/tml.2023.1683f
The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The FDA has granted regular approval to dostarlimabgxly ( Jemperli – GSK), an immune checkpoint inhibitor, for treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial…
Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e64-5 doi:10.58347/tml.2023.1673h
The FDA has granted regular approval to dostarlimabgxly ( Jemperli – GSK), an immune checkpoint inhibitor, for treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation. Dostarlimab received accelerated approval in 2021 for treatment of adults with dMMR recurrent or advanced endometrial cancer or nonendometrial solid tumors that progressed on or following prior treatment and who have no satisfactory alternative treatment options. About 25-30% of patients with endometrial cancer have dMMR tumors.
